We read with interest these 2 separate correspondences, both authored by employees of Aimmune Therapeutics.1,2 We certainly appreciate their interest in our qualitative research study about motivations for seeking peanut allergy therapy.3 With the potential approval of 2 drugs to help treat peanut allergy in the next year, this is a timely topic. Both queries highlight alleged problems regarding our methods and conclusion and voice rather fervent, somewhat misplaced, comments and inappropriate posturing regarding Aimmune's interpretation of DBV's topline data for their phase 3 trial. (Source: Annals of Allergy, Asthma and Immunology)
MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RlLT7h
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.